<?xml version="1.0"?>
<rss version="2.0" xmlns:prism="http://purl.org/rss/1.0/modules/prism/">
  <channel>
    <title>Antibody Therapeutics Advance Access</title>
    <link>https://dbpia.nl.go.kr/abt</link>
    <description>
    </description>
    <language>en-us</language>
    <pubDate>Sun, 08 Nov 2026 00:00:00 GMT</pubDate>
    <lastBuildDate>Sun, 08 Nov 2026 07:47:29 GMT</lastBuildDate>
    <generator>Silverchair</generator>
    <item>
      <title>Potent Antitumor Efficacy of a Novel ALPPL2/ALPP-Targeting Antibody-Drug Conjugate in Preclinical Models</title>
      <link>https://dbpia.nl.go.kr/abt/advance-article/doi/10.1093/abt/tbag055/9022171?rss=1</link>
      <pubDate>Sun, 08 Nov 2026 00:00:00 GMT</pubDate>
      <description>&lt;span class="paragraphSection"&gt;&lt;div class="boxTitle"&gt;Abstract:&lt;/div&gt;&lt;div class="boxTitle"&gt;Background&lt;/div&gt;The antitumor efficacy of antibody-drug conjugates (ADCs) is primarily determined by the tissue-specific distribution of target antigens. Placental alkaline phosphatase-like protein 2 (ALPPL2) and placental alkaline phosphatase (ALPP) are highly homologous and aberrantly overexpressed in multiple human malignancies, while minimally expressed in most normal adult tissues, rendering them ideal targets for tumor-targeted therapeutics. However, ALPPL2/ALPP-targeted therapeutics remain in their infancy, with no clinically approved agents, presenting a significant translational opportunity.&lt;div class="boxTitle"&gt;Methods&lt;/div&gt;Antibodies were prepared via hybridoma technology. Their binding specificity, affinity, cross-species reactivity and internalization were characterized using flow cytometry and biolayer interferometry (BLI). Competitive epitope binning was applied to delineate the epitope diversity. Lead candidates were conjugated with monomethyl auristatin E (MMAE) to construct ALPPL2 ADCs, and their antitumor potency was systematically evaluated &lt;span style="font-style:italic;"&gt;in vitro&lt;/span&gt; and &lt;span style="font-style:italic;"&gt;in vivo&lt;/span&gt; across various tumor models.&lt;div class="boxTitle"&gt;Results&lt;/div&gt;A panel of chimeric antibodies featuring high affinity, high specificity, and rapid internalization was generated and grouped into discrete epitope bins. The lead candidate AL71 shares substantial but non-identical epitope overlap with the benchmark SGN-ALPV and displays improved cross-reactivity against cynomolgus monkey ALPP. Critically, AL71-ADC surpasses SGN-ALPV, demonstrating enhanced &lt;span style="font-style:italic;"&gt;in vitro&lt;/span&gt; cytotoxicity across multiple tumor cell models and potent &lt;span style="font-style:italic;"&gt;in vivo&lt;/span&gt; antitumor activity in xenograft models.&lt;div class="boxTitle"&gt;Conclusions&lt;/div&gt;AL71-ADC generated herein exhibits superior preclinical antitumor efficacy and cross-species reactivity relative to benchmark SGN-ALPV. Given the tumor-restricted expression of ALPPL2/ALPP alongside unmet clinical demands, AL71-ADC represents a promising therapeutic candidate for the treatment of ALPPL2/ALPP-positive malignancies.&lt;/span&gt;</description>
      <prism:startingPage xmlns:prism="prism">tbag055</prism:startingPage>
      <prism:doi xmlns:prism="prism">10.1093/abt/tbag055</prism:doi>
      <guid>http://doi.org/10.1093/abt/tbag055</guid>
    </item>
    <item>
      <title>Engineering a novel asymmetric head-to-tail (HtT) 1+1 and 2+1 T cell bispecific antibody (TCB) platform with superior T cell killing compared to 1+1 bispecific IgG antibodies</title>
      <link>https://dbpia.nl.go.kr/abt/advance-article/doi/10.1093/abt/tbag057/9022167?rss=1</link>
      <pubDate>Sun, 08 Nov 2026 00:00:00 GMT</pubDate>
      <description>&lt;span class="paragraphSection"&gt;&lt;div class="boxTitle"&gt;Abstract&lt;/div&gt;Background: The overall activity of T cell engaging bispecific antibodies (TCBs) is governed by an interplay of various factors including antigen density, binding epitope, affinity, and molecular geometry. Conventional 1+1 IgG-like-TCBs represent the most utilized format amongst approved TCBs and offer prolonged pharmacokinetics via silenced Fc domains. Nevertheless, head-to-tail (HtT) formats, such as the 2+1 TCBs, have gained interest more recently.Methods: Here, we systematically evaluated HtT configurations, including 1+1 one-armed (OA), 2+1 classical, and 2+1 inverted TCB formats, against standard 1+1 IgG-like TCBs across CEACAM5, FOLR1, MCSP, and CD20 as tumor antigens. Assessments included &lt;span style="font-style:italic;"&gt;in vitro&lt;/span&gt; functional assays, &lt;span style="font-style:italic;"&gt;in vivo&lt;/span&gt; humanized mouse models, and biophysical characterization via negative-stain transmission electron microscopy (NS-TEM) and liquid-state atomic force microscopy (AFM).Results&lt;strong&gt;:&lt;/strong&gt; HtT geometries consistently outperformed standard 1+1 IgG-like TCBs in tumor cell lysis, T-cell activation, and tumor growth inhibition. Biophysical analyses confirmed that the 2+1 inverted format possesses exceptional conformational flexibility, behaving as freely jointed rigid segments. Crucially, by positioning the CD3-binding site internally, the 2+1 inverted format circumvents N-terminal steric restrictions of the tumor antigen binder, preserving high-avidity tumor engagement. Furthermore, &lt;span style="font-style:italic;"&gt;in vivo&lt;/span&gt; evaluation demonstrated that the HtT configuration remains highly efficacious in combination with standard bivalent CD20 monoclonal antibodies.Conclusions: The asymmetric inverted configurations of TCBs represent a robust, versatile, and highly combinable platform for next-generation TCB design.&lt;/span&gt;</description>
      <prism:startingPage xmlns:prism="prism">tbag057</prism:startingPage>
      <prism:doi xmlns:prism="prism">10.1093/abt/tbag057</prism:doi>
      <guid>http://doi.org/10.1093/abt/tbag057</guid>
    </item>
    <item>
      <title>Hetero-hexamerization as a means to improve broadly neutralizing antibody activity against HIV-1</title>
      <link>https://dbpia.nl.go.kr/abt/advance-article/doi/10.1093/abt/tbag056/9016065?rss=1</link>
      <pubDate>Fri, 06 Nov 2026 00:00:00 GMT</pubDate>
      <description>&lt;span class="paragraphSection"&gt;&lt;div class="boxTitle"&gt;Abstract&lt;/div&gt;&lt;div class="boxTitle"&gt;Background&lt;/div&gt;Broadly neutralizing antibodies (bnAbs) offer a promising approach for HIV-1 prevention and therapy. Development efforts have primarily focused on maximizing neutralization breadth and potency, with clinical trials now selecting bnAb combinations to maximize HIV envelope coverage and limit viral escape. Antibody Fc domain engineering provides an additional opportunity to improve antibody potency by enhancing Fc-mediated effector functions such as lysis mediated by activation of the classical complement cascade, which may also be enhanced in the context of antibody combinations.&lt;div class="boxTitle"&gt;Methods&lt;/div&gt;To engineer monoclonal antibodies (mAbs) with enhanced complement activity, the E430G (EG) mutation, which promotes Fc hexamerization, resulting in enhanced engagement of the six heads of the cascade initiator C1q, was incorporated into a panel of anti-HIV-1 mAbs. The panel of modified and unmodified antibodies were tested for antigen binding and neutralization, Fc receptor binding and effector function, and complement cascade initiation and viral lysis activity &lt;span style="font-style:italic;"&gt;in vitro&lt;/span&gt;.&lt;div class="boxTitle"&gt;Results&lt;/div&gt;We demonstrate that the EG mutation selectively enhances complement activity while preserving neutralization, antibody-dependent cellular cytotoxicity and phagocytosis. Moreover, combinations of EG-modified mAb combinations further boosted complement activation relative to individual antibodies or equivalent mixtures of unmodified mAbs, consistent with formation of hetero-hexamers.&lt;div class="boxTitle"&gt;Conclusions&lt;/div&gt;These findings show that Fc engineering and antibody combinations can synergize to improve antiviral bnAb breadth and potency, suggesting a potential path toward more effective mAb-based strategies to prevent or treat HIV-1 infection.&lt;/span&gt;</description>
      <prism:startingPage xmlns:prism="prism">tbag056</prism:startingPage>
      <prism:doi xmlns:prism="prism">10.1093/abt/tbag056</prism:doi>
      <guid>http://doi.org/10.1093/abt/tbag056</guid>
    </item>
  </channel>
</rss>